Incidence of deep vein thrombosis is increased with 30 mg twice daily dosing of enoxaparin compared with 40 mg daily

American Journal of Surgery

Volumn 203, Issue 5, 2012, Pages 598-602

  Riha, Gordon M ^a   Van, Philbert Y ^a   Differding, Jerome A ^a   Schreiber, Martin A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

30 BID; 40 QD; DVT; Enoxaparin; Surgery; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURGICAL PATIENT; ULTRASOUND;

EID: 84859910803     PISSN: 00029610     EISSN: 18791883     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2011.12.008     Document Type: Article

References (18)

1. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA 2003;290:1868-74. (Pubitemid 37430603)
2. MacDougall DA, Feliu AL, Boccuzzi SJ, et al. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006;63(Suppl 6):S5-15.
3. Mismetti P, Laporte S, Darmon JY, et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913-30. (Pubitemid 34015572)
4. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;335:701-7. (Pubitemid 26287356)
5. Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001;83:900-6. (Pubitemid 32523810)
6. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(Suppl):381S-453S. (Pubitemid 351894916)
7. Spiro TE, Johnson GJ, Christie MJ, et al. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Enoxaparin clinical trial group. Ann Intern Med 1994;121:81-9. (Pubitemid 24203489)
8. Hebbeler SL, Marciniak CM, Crandall S, et al. Daily vs twice daily enoxaparin in the prevention of venous thromboembolic disorders during rehabilitation following acute spinal cord injury. J Spinal Cord Med 2004;27:236-40. (Pubitemid 44210647)
9. Bush S, Leclaire A, Hampp C, et al. Review of a large clinical series: once- versus twice-daily enoxaparin for venous thromboembolism prophylaxis in high-risk trauma patients. J Intensive Care Med 2011;26:111-5.
10. Kakkar AK, Cohen AT, Tapson VF, et al. Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients. Ann Surg 2010;251:330-8.
11. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin clinical trial group. J Bone Joint Surg Am 1994;76:3-14. (Pubitemid 24081799)
12. Brophy DF, Martin EJ, Best AM, et al. Antifactor xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction. J Thromb Haemost 2004;2:1299-304. (Pubitemid 40186124)
13. Bara L, Planes A, Samama MM. Occurrence of thrombosis and haemorrhage, relationship with anti-xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999;104:230-40. (Pubitemid 29083328)
14. Malinoski D, Jafari F, Ewing T, et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma Inj Infect Crit Care 2010;68:874-80.
15. Rutherford EJ, Schooler WG, Sredzienski E, et al. Optimal dose of enoxaparin in critically ill trauma and surgical patients. J Trauma Inj Infect Crit Care 2005;58:1167-70. (Pubitemid 41020100)
16. Mayr AJ, Dünser M, Jochberger S, et al. Antifactor xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res 2002;105:201-4. (Pubitemid 34260941)
17. Priglinger U, Delle Karth G, Geppert A, et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit Care Med 2003;31:1405-9. (Pubitemid 36583851)
18. Van PY, Cho SD, Underwood SJ, et al. Thrombelastography versus Antifactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients. J Trauma 2009;66(6):1509-15.